Diagnosis, Risk-Stratification, Management Updates in Myelodysplastic Syndromes
An overview of the diagnosis and management of MDS, including recent treatment, was discussed in a paper published in the American Journal of Hematology.
Hematologic Cancers News
HEMATOLOGIC CANCER ADVISOR
Hematologic Cancers News
How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
BCMA-Directed CAR T Cell Therapy Gets Priority Review for Multiple Myeloma
The BLA is supported by data from the open-label, single-arm phase 2 KarMMa study.
Venetoclax With 10-day Decitabine May Induce High Activity in High-Risk Acute Myeloid Leukemia
Patients with newly diagnosed AML who are ineligible for intensive chemotherapy may benefit from a 10-day course of decitabine with venetoclax.
Rapid Third-Infusion Protocol of Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma
An observational study determined that 90-minute rapid infusions of daratumumab for RRMM was safe and well-tolerated.
Opposition to a European Patent for CAR-T Therapy: A Mechanism to Control High Drug Prices?
The nongovernmental organizations argued that patents for this CAR-T should never have been granted in the first place because the underlying technology is not novel.
Triple Therapy for CLL Shows Promise in Phase 2 Trial
Most patients achieved deep remission after a 14-month regimen of obinutuzumab, ibrutinib, and venetoclax.
Recall of Specific Types of Breast Implants and Tissue Expanders Has Far-Reaching Impact on Patients With Breast Cancer
In Japan, insurance coverage for breast implantation is limited to procedures using Allergen-manufactured products.
Rivaroxaban May Be a Suitable Alternative to Low-Molecular Weight Heparin in Cancer-Associated Thrombosis
Among some patients with cancer-associated thrombosis, rivaroxaban may be a viable alternative to low-molecular-weight heparin.
Hepatosplenic T-cell Lymphoma: Recent Progress and Future Considerations
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.
Venetoclax With a Hypomethylating Agent Effective in Treatment-Naive or Relapsed/Refractory Acute Myeloid Leukemia
Regardless of genotype, venetoclax with a hypomethylating agent yields strong response and survival outcomes among patients with treatment-naive or R/R AML.
Uncommon Mutation in CLL Associated With More Favorable Prognostic Factors
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who had an L265P MYD88 mutation were uncommon and had distinct features.
Eltrombopag: Noninferior to Intravenous Immunoglobulin in Immune Thrombocytopenia?
Eltrombopag may be an effective alternative to intravenous immunoglobulin for the perioperative treatment of immune thrombocytopenia.
Multiple Myeloma: More Real-World Data Needed To Confirm Effectiveness of New Treatments
More data is needed to determine whether newer treatments are truly improving outcomes among patients with r/r multiple myeloma.
Risk-Adapted Bendamustine and Rituximab: An Alternative for Older Individuals With CLL
Risk-adapted dosing of bendamustine and rituximab may be beneficial and tolerable for elderly patients with CLL, a retrospective study found.
Radiotherapy Response Time Did Not Dictate Outcomes for Gastrointestinal Low-Grade B-Cell Lymphoma
Delayed evaluation could decrease unnecessary invasive tests.
COVID-19, SARS-CoV-2 Infection Phenotypes Vary With Different Tumor Subtypes
Among patients with cancer, tumor subtypes may influence varying susceptibility to SARS-CoV-2 and COVID-19 disease phenotypes.
Outcomes After Daratumumab Addition to Induction Therapy in Newly Diagnosed Multiple Myeloma
Researchers assessed the effects of adding daratumumab to standard frontline induction therapy to treat MM in newly diagnosed, transplant-eligible patients.
Fostering Trust Between Parents of Children With Cancer and Physicians
Although most parents of children with cancer form trusting relationships with their children’s oncologists, poor outcomes may negatively affect this.
Waldenström Macroglobulinemia Treated With Ixazomib Combination Therapy: Long-Term Follow-Up
Investigators measured ixazomib, dexamethasone, and rituximab combination treatment among patients with treatment-naive Waldenström macroglobulinemia.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
